Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.

Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients.

Although cytomegalovirus (CMV) specific cell-mediated immunity (CMI) has been suggested as a predictive marker for CMV infection, proper CMI monitoring strategy in CMV-seropositive recipients and optimal method are not defined. The aim of this study was to evaluate two interferon gamma release assay...

Full description

Bibliographic Details
Main Authors:	Hyeyoung Lee, Ki Hyun Park, Ji Hyeong Ryu, Ae-Ran Choi, Ji Hyun Yu, Jihyang Lim, Kyungja Han, Sang Il Kim, Chul Woo Yang, Byung Ha Chung, Eun-Jee Oh
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5726762?pdf=render

Similar Items

Torque teno virus viremia and QuantiFERON®-CMV assay in prediction of cytomegalovirus reactivation in R+ kidney transplant recipients
by: Sarah Mafi, et al.
Published: (2023-06-01)

QuantiFERON CMV Test and CMV Serostatus in Lung Transplant: Stratification Risk for Infection, Chronic and Acute Allograft Rejection
by: Paolo Solidoro, et al.
Published: (2024-08-01)

Predicting cytomegalovirus infection and graft-versus-host disease using QuantiFERON-CMV and Monitor in pediatric transplants: a proof-of-concept study
by: Lina Souan, et al.
Published: (2025-02-01)

Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients
by: Dominika Deborska-Materkowska, et al.
Published: (2018-04-01)

Comparison of LIAISON QuantiFERON-TB Gold Plus with QuantiFERON-TB Gold Plus
by: Kamran Kadkhoda, et al.
Published: (2023-02-01)

Oral Valganciclovir as a Preemptive Treatment for Cytomegalovirus (CMV) Infection in CMV-Seropositive Liver Transplant Recipients.
by: Jong Man Kim, et al.
Published: (2015-01-01)

Unusual interferon gamma measurements with QuantiFERON-TB Gold and QuantiFERON-TB Gold In-Tube tests.
by: Richard D Powell, et al.
Published: (2011-01-01)

QuantiFERON-Cytomegalovirus Assay for Prediction of Cytomegalovirus Viremia in Kidney Transplant Recipients: Study From High Cytomegalovirus Seroprevalence Country
by: Kritsada Pongsakornkullachart, et al.
Published: (2022-05-01)

QuantiFERON-TB Gold PLUS versus QuantiFERON-TB Gold In-Tube test for diagnosing tuberculosis infection
by: Soo Han Kim, et al.
Published: (2020-03-01)

Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON-CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications.
by: Siok-Keen Tey, et al.
Published: (2013-01-01)

QuantiFERON-TB reversion in children and adolescents with tuberculosis
by: Paula Rodríguez-Molino, et al.
Published: (2024-03-01)

QuantiFERON® TB GOLD’ s applications in the tuberculosis disease
by: Maria Saladino, et al.
Published: (2014-06-01)

Cytomegalovirus (CMV)-Specific Perforin and Granzyme B ELISPOT Assays Detect Reactivation of CMV Infection in Inflammatory Bowel Disease
by: Paul V. Lehmann, et al.
Published: (2012-04-01)

Evaluating the diagnostic accuracy of QIAreach QuantiFERON-TB compared to QuantiFERON-TB Gold Plus for tuberculosis: a systematic review and meta-analysis
by: Shima Mahmoudi, et al.
Published: (2024-06-01)

Comparison of the change in QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold In-Tube results after preventive therapy for latent tuberculosis infection.
by: Ock-Hwa Kim, et al.
Published: (2020-01-01)

QuantiFERON® TB Gold IT in the diagnosis of active pulmonary TB
by: Clara Fabris, et al.
Published: (2010-03-01)

Prevalence of latent tuberculosis infection among foreign students in Lübeck, Germany tested with QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus
by: Elia Noemi Gallegos Morales, et al.
Published: (2017-05-01)

Comparison of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold-Plus in the Diagnosis of Mycobacterium tuberculosis Infections in Immunocompromised Patients: a Real-World Study
by: Yuzhen Xu, et al.
Published: (2022-04-01)

Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
by: Euri Seo, et al.
Published: (2021-01-01)

Accuracy of QuantiFERON-TB Gold Test for Tuberculosis Diagnosis in Children.
by: Michela Sali, et al.
Published: (2015-01-01)

QuantiFERON-TB gold test versus tuberculin skin test
by: Wiwanitkit Viroj
Published: (2010-01-01)

Correction: Immunologic monitoring of cytomegalovirus (CMV) enzyme-linked immune absorbent spot (ELISPOT) for controlling clinically significant CMV infection in pediatric allogeneic hematopoietic stem cell transplant recipients.
by: Euri Seo, et al.
Published: (2023-01-01)

Comparative Evaluation of Standard E TB-Feron ELISA and QuantiFERON-TB Gold Plus Assays in Patients with Tuberculosis and Healthcare Workers
by: In Young Yoo, et al.
Published: (2021-09-01)

Serial QuantiFERON-TB Gold testing in patients with psoriasis treated with ustekinumab.
by: Chuan-Yu Hsiao, et al.
Published: (2017-01-01)

The Pitfalls of Mining for QuantiFERON Gold in Severely Ill Patients With COVID-19
by: Melissa P. Cortes, MD, et al.
Published: (2022-10-01)

Performance and variability of QuantiFERON Gold Plus assay associated with phlebotomy type.
by: Saroochi Agarwal, et al.
Published: (2018-01-01)

Analysis of cellular and soluble profiles in QuantiFERON nonconverters, converters, and reverters in the Gambia
by: Lydia Medawar, et al.
Published: (2019-12-01)

From Latent Tuberculosis Infection to Tuberculosis. News in Diagnosticsb (QuantiFERON-Plus)
by: Dagmara I. Borkowska, et al.
Published: (2017-03-01)

Negative effect of smoking on the performance of the QuantiFERON TB gold in tube test
by: Aabye Martine G, et al.
Published: (2012-12-01)

Tuberculin skin test and QuantiFERON test for detection of latent Mycobacterium tuberculosis
by: M.M.G.F. Elmahdy, et al.
Published: (2014-04-01)

Within-subject interlaboratory variability of QuantiFERON-TB gold in-tube tests.
by: William C Whitworth, et al.
Published: (2012-01-01)

Predicting Healthcare-Associated Infection in Patients with Pneumonia via QuantiFERON®-Monitoring
by: Kim T, et al.
Published: (2025-03-01)

QuantiFERON-TB Gold In-Tube test in active tuberculosis patients and healthy adults
by: Benjawan Phetsuksiri, et al.
Published: (2018-10-01)

Improved Performance of the QuantiFERON-SARS-CoV-2 Assay with the Extended Set
by: Lydia Lamara Mahammed, et al.
Published: (2023-05-01)

Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients
by: Sheng-Wei Pan, et al.
Published: (2023-10-01)

Beyond QuantiFERON-TB Results, the Added Value of a Weak Mitogen Response
by: Marine Jacquier, et al.
Published: (2022-05-01)

Diagnostic utility of QuantiFERON-TB gold (QFT-G) in active pulmonary tuberculosis
by: Ahmed Anwar, et al.
Published: (2015-01-01)

Use of QuantiFERON®-TB Gold in-tube culture supernatants for measurement of antibody responses.
by: Simon G Kimuda, et al.
Published: (2017-01-01)

Clinical utility of QuantiFERON TB Gold Test in the diagnosis of latent tuberculosis infections
by: Salvatore Nisticò, et al.
Published: (2010-03-01)

Evaluation of the performance of QuantiFERON®-TB Gold plus test in active tuberculosis patients
by: Cengiz Çavuşoğlu, et al.
Published: (2021-05-01)